Research programme: Alzheimer's disease therapeutics - Denali Therapeutics
Alternative Names: OTV:MAPTLatest Information Update: 25 Mar 2024
At a glance
- Originator Denali Therapeutics Inc
- Class Antidementias; Antisense oligonucleotides
- Mechanism of Action Gene silencing; Tau protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease